Title |
Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting
|
---|---|
Published in |
Journal of Asthma and Allergy, May 2012
|
DOI | 10.2147/jaa.s29811 |
Pubmed ID | |
Authors |
Ayad K Ali, Abraham G Hartzema |
Abstract |
Omalizumab is a monoclonal antibody, indicated for the treatment of severe allergic asthma. In Europe, there have been concerns about the cardiovascular safety of omalizumab. The objective of this study was to analyze the association between omalizumab and arterial thrombotic events in a spontaneous adverse drug reaction reporting database in the US. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 22% |
Australia | 1 | 11% |
Argentina | 1 | 11% |
Unknown | 5 | 56% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 56% |
Practitioners (doctors, other healthcare professionals) | 3 | 33% |
Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Finland | 1 | 3% |
Unknown | 36 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 16% |
Student > Master | 6 | 16% |
Researcher | 5 | 14% |
Student > Bachelor | 4 | 11% |
Student > Doctoral Student | 2 | 5% |
Other | 7 | 19% |
Unknown | 7 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 27% |
Biochemistry, Genetics and Molecular Biology | 4 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
Engineering | 2 | 5% |
Immunology and Microbiology | 2 | 5% |
Other | 7 | 19% |
Unknown | 9 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2012.
All research outputs
#6,438,690
of 25,584,565 outputs
Outputs from Journal of Asthma and Allergy
#171
of 536 outputs
Outputs of similar age
#42,166
of 176,069 outputs
Outputs of similar age from Journal of Asthma and Allergy
#3
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 536 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.